Skip to main content

Research Repository

Advanced Search

Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK

Goodwin, Amanda T.; Thompson, Jonathan S.; Hall, Ian P.

Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK Thumbnail


Authors

AMANDA GOODWIN Amanda.Goodwin2@nottingham.ac.uk
Clinical Assistant Professor (Nihr Clinical Lecturer in Respiratory Medicine)

Jonathan S. Thompson

IAN HALL IAN.HALL@NOTTINGHAM.AC.UK
Professor of Molecular Medicine



Contributors

Seung-Hwa Lee
Editor

Abstract

Introduction Antivirals, such as molnupiravir, and SARS-CoV-2 neutralising monoclonal antibodies (nMAbs), such as sotrovimab, reduced the risk of hospitalisation and death in clinical trials of high-risk non-hospitalised patients with Covid-19. However, the real-world benefits of these drugs are unclear. Aims To evaluate the characteristics and outcomes of high-risk patients referred for outpatient antiviral or nMAb treatment for symptomatic Covid-19. Methods The records of patients referred to a large UK Covid Medicines Delivery Unit (CMDU) over nine weeks (December 2021-February 2022) were reviewed. Data were collected on demographics, referral indications, vaccination, deprivation, treatment, complications, hospital admission, and mortality. Results 1820 patients were referred to the CMDU, with 604 (33.2%) suitable for further assessment. 169 patients received sotrovimab, 80 patients received molnupiravir, 70 patients declined treatment, and 266 were ineligible for treatment because of resolving symptoms. There were trends towards higher proportions of female and white patients, lower deprivation scores, and malignancy- or transplant-related indications in the groups receiving treatment compared with untreated patients. Covid-19-related hospitalisations occurred in 1.2% of the treated group and 3.0% of the untreated group indicating a potential treatment effect, however Covid-related hospitalisations were lower than reported in the original clinical trials (2.2% compared with 7–10%). Conclusion The referral pathways for outpatient treatment of Covid-19 are inefficient, and the UK system may not be serving all groups equitably. Hospitalisation with Covid-19 was rare regardless of treatment. Ongoing service evaluation is required to ensure efficient use of resources for the outpatient management of Covid-19.

Citation

Goodwin, A. T., Thompson, J. S., & Hall, I. P. (2023). Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK. PLoS ONE, 18(3), Article e0281915. https://doi.org/10.1371/journal.pone.0281915

Journal Article Type Article
Acceptance Date Feb 5, 2023
Online Publication Date Mar 15, 2023
Publication Date Mar 15, 2023
Deposit Date Mar 17, 2023
Publicly Available Date Mar 22, 2023
Journal PLoS ONE
Electronic ISSN 1932-6203
Publisher Public Library of Science
Peer Reviewed Peer Reviewed
Volume 18
Issue 3
Article Number e0281915
DOI https://doi.org/10.1371/journal.pone.0281915
Keywords Research Article, Medicine and health sciences, Biology and life sciences
Public URL https://nottingham-repository.worktribe.com/output/18529236
Publisher URL https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0281915

Files





You might also like



Downloadable Citations